Medmira (TSE:MIR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MedMira Inc. has announced the launch of clinical trials for its innovative Multiplo Complete Syphilis Antibody Test in Canada, aiming to offer a rapid and cost-effective solution for syphilis healthcare. The test, which is unique in providing both screening and confirmation in under 3 minutes, is expected to be a significant addition to the Canadian healthcare sector in addressing the syphilis health crisis. The trials are supported by a partnership with REACH Nexus and funded by the Canadian Institute of Health Research.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.
